Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
---|---|---|---|---|---|---|---|---|---|
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €150→€148 | ― | 1.90% | Reiterated | |||||
Alstom SA | HOLD €24 | ― | -14.40% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €134→€136 | ― | 14.10% | Reiterated | ||||
Alstom SA | BUY €26 | ― | -7.70% | Reiterated | J.P. Morgan Sticks to Its Buy Rating for Alstom SA (0J2R) | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL €265 | ― | 0.60% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €28.3 | ― | 3.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €20 | ― | 8.40% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €153→€156 | ― | 8.30% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €14 | ― | 15.90% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €22→€24 | ― | 1.40% | Upgraded | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €5.6 | ― | 14.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €75 | ― | 6.80% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €67→€61 | ― | 3.20% | Reiterated | ||||
Arkema | SELL €68.5→€65 | ― | -2.50% | Reiterated | Arkema SA (AKE:FP) (ARKAF) PT Lowered to EUR65 at JPMorganJPMorgan analyst Chetan Udeshi lowered the price target on Arkema SA (AKE:FP) (OTC: ARKAF) to EUR65.00 (from EUR68.50) while maintaining a Underweight rating. | ||||
UBISOFT Entertainment | HOLD €13→€12 | ― | -25.90% | Reiterated | Ubisoft Entertainment SA (UBI:FP) (UBSFY) PT Lowered to EUR12 at Deutsche BankDeutsche Bank analyst George Brown lowered the price target on Ubisoft Entertainment SA (UBI:FP) (OTC: UBSFY) to EUR12.00 (from EUR13.00) while maintaining a Hold rating. | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €4.5→€4 | ― | 1.30% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €1.8 | ― | 9.50% | Initiated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €65 | ― | 4.10% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €18→€19 | ― | 14.10% | Reiterated | ||||
Teleperformance | BUY €190 | ― | -3.70% | Reiterated | Berenberg Bank Sticks to Its Buy Rating for Teleperformance (0J6X) | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL €26.4 | ― | 10.30% | Reiterated | ||||
Hermes International | BUY €2,600 | ― | -5.40% | Initiated | Hermes initiated with an Outperform at RBC Capital | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €95→€93 | ― | 12.90% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €183 | ― | 20.40% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €239→€235 | ― | 5.00% | Downgraded | |||||
Pernod Ricard | HOLD €103→€98 | ― | -1.10% | Reiterated | Pernod Ricard price target lowered to EUR 98 from EUR 103 at Morgan Stanley | ||||
Robertet | BUY €1,090 | ― | -1.80% | Initiated | Robertet (0NZN) Receives a New Rating from Berenberg Bank | ||||
MaaT Pharma | BUY €22 | ― | -18.60% | Reiterated | Promising ALS Trial Results Bolster Buy Rating for MaaT Pharma Amidst Strategic Oncology Focus | ||||
Sanofi | BUY €114→€124 | ― | -1.40% | Reiterated | Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), Healthequity (HQY) | ||||
Bouygues | HOLD €37 | ― | 1.00% | Reiterated | Kepler Capital Sticks to Its Hold Rating for Bouygues (0HAN) | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €85 | ― | 2.70% | Reiterated | ||||
MaaT Pharma | BUY €15.5 | ― | -13.70% | Reiterated | Kepler Capital Remains a Buy on MaaT Pharma (MAAT) | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €38 | ― | 18.10% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €55.3 | ― | 1.10% | Upgraded | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €3.2→€3.7 | ― | 10.00% | Reiterated |